Axa
CBIO

Axa’s Crescent Biopharma CBIO Stock Holding History

Axa’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,877
Closed -$4.76M – 1093
2024
Q1 		$4.76M Buy
15,877
+4
+0% +$1.2K 0.01% 566
2023
Q4 		$3.75M Sell
15,873
-384
-2% -$59.7K 0.01% 611
2023
Q3 		$2.44M Sell
16,257
-58
-0.4% -$9.15K 0.01% 673
2023
Q2 		$2.84M Buy
16,315
+224
+1% +$37.6K 0.01% 663
2023
Q1 		$2.03M Buy
+16,091
New +$3.62M 0.01% 761
2020
Q2 		– Sell
-306
Closed -$70K – 1256
2020
Q1 		$70K Sell
306
-9,146
-97% -$3.5M ﹤0.01% 1150
2019
Q4 		$5M Buy
9,452
+323
+4% +$175K 0.02% 620
2019
Q3 		$3.93M Sell
9,129
-177
-2% -$114K 0.02% 720
2019
Q2 		$11.1M Buy
9,306
+55
+0.6% +$65.8K 0.04% 447
2019
Q1 		$11.5M Buy
9,251
+159
+2% +$182K 0.05% 423
2018
Q4 		$8.61M Buy
9,092
+1,834
+25% +$2.21M 0.04% 462
2018
Q3 		$10.5M Buy
7,258
+1,129
+18% +$1.71M 0.04% 472
2018
Q2 		$9.89M Buy
6,129
+1,043
+21% +$1.79M 0.04% 455
2018
Q1 		$8.26M Sell
5,086
-24
-0.5% -$49.9K 0.03% 512
2017
Q4 		$8.58M Buy
+5,110
New +$6.76M 0.03% 516

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Axa's CBIO Position: Q2 2024 in Review

Axa sold out of Crescent Biopharma (CBIO) in Q2 2024, closing a stake of 15,877 shares — an estimated $4.76M sold.

Axa first reported a position in CBIO in Q4 2017 and held it in 15 quarters. The position peaked at $11.5M in Q1 2019. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2024.

  • Axa reported no remaining Crescent Biopharma position as of Q2 2024 after selling out during the quarter.
  • Axa sold 15,877 Crescent Biopharma shares in Q2 2024, an estimated $4.76M.
  • Axa first reported a position in Crescent Biopharma in Q4 2017 and held it in 15 quarters.
  • Axa's Crescent Biopharma position peaked at $11.5M in Q1 2019.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2024.

Based on Axa's 13F filing for Q2 2024, filed 14 Aug 2024.